Initial antibiotic therapy for severe PID

For patients with severe PID who have sepsis or septic shock, start antibiotic therapy within 1 hour of presentation to medical care or, for ward-based patients, development of sepsis or septic shock. Antibiotics should be administered immediately after blood samples are taken for culture. Collect an endocervical swab sample as soon as possible; however, do not delay antibiotic administration to do so. For nonantibiotic management of sepsis or septic shock, see Resuscitation of patients with sepsis or septic shock.

Rarely, patients who are critically ill may have infection caused by Streptococcus pyogenes (group A streptococcus [GAS]); see Streptococcus pyogenes bloodstream infections, including toxic shock syndrome.

Empirical regimens may need to be modified according to local epidemiology, if known, and consideration given to the potential relevance of the patient’s recent microbiology results. For patients with risk factors for infection with a multidrug-resistant gram-negative bacterium, seek advice from a clinical microbiologist or infectious diseases physician.

For empirical therapy in patients who are pregnant or who have features of severe PID, as a 3-drug regimen, useOng, 2023:

ceftriaxone 2 g intravenously, daily; for adults with septic shock or requiring intensive care support, use 1 g intravenously, 12-hourly1. See advice on modification and duration of therapy ceftriaxone ceftriaxone ceftriaxone

PLUS

azithromycin 500 mg intravenously, daily. See advice on modification and duration of therapy azithromycin azithromycin azithromycin

PLUS

metronidazole 500 mg intravenously, 12-hourly. See advice on modification and duration of therapy. metronidazole metronidazole metronidazole

For patients who have had a nonsevere (immediate or delayed) hypersensitivity reaction to a penicillin, use the regimen above.

For patients who have had a severe immediate2 hypersensitivity reaction to a penicillin, the regimen above can be considered if a beta-lactam antibiotic is strongly preferred (for considerations, see Severe immediate hypersensitivity: Implications of cross-reactivity between penicillins and cephalosporins).

For patients who have had a severe immediate2 hypersensitivity reaction to a penicillin in whom the regimen above is not used, or for patients who have had a severe delayed3 hypersensitivity reaction to a penicillin, as a 3-drug regimen, useOng, 2023Ross, 2017Savaris, 2020Workowski, 2021:

1gentamicin intravenously; see Gentamicin initial dose calculator for adults for initial dose. See Principles of aminoglycoside use for prescribing considerations and subsequent dosing. See advice on modification and duration of therapy gentamicin gentamicin gentamicin

OR

1tobramycin intravenously; see Tobramycin initial dose calculator for adults for initial dose. See Principles of aminoglycoside use for prescribing considerations and subsequent dosing. See advice on modification and duration of therapy tobramycin tobramycin tobramycin

PLUS with either of the above drugs

azithromycin 500 mg intravenously, daily. See advice on modification and duration of therapy azithromycin azithromycin azithromycin

PLUS

clindamycin 600 mg intravenously, 8-hourly. See advice on modification and duration of therapy4. clindamycin clindamycin clindamycin

1 To ensure adequate drug exposure, a modified dosage of ceftriaxone is recommended for patients with septic shock or those requiring intensive care support because pharmacokinetics may be altered in patients with critical illness (eg because of enhanced kidney clearance or changes in volume of distribution). Once the critical illness has resolved, consider switching to the standard dosage.Return
2 Severe immediate hypersensitivity reactions include anaphylaxis, compromised airway, airway angioedema, hypotension and collapse.Return
3 Severe delayed hypersensitivity reactions include cutaneous adverse drug reactions (eg drug rash with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], severe blistering or desquamative rash), and significant internal organ involvement (eg acute interstitial nephritis).Return
4 There are more clinical and microbiological data to support the use of clindamycin than lincomycin. Intravenous lincomycin can be used at the same dosage if clindamycin is unavailable or if a local protocol recommends its use.Return